Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Academy of Military Medical Sciences, Shanghai Pulmonary Hospital, Tongji University, Capital Medical University, Beijing Chest Hospital, Daping Hospital, Army Medical University, Second Military Medical University, Changhai Hospital, 81th Hospital of PLA, Central South University, Second Xiangya Hospital of Central South University, Zhejiang Cancer Hospital, Hunan Cancer Hospital, Jilin Province Tumor Hospital, Jiangsu Cancer Hospital, Air Force Medical University, Nanjing General Hospital of Nanjing Military Command, Guangdong Academy of Medical Sciences, Guangdong General Hospital, First Affiliated Hospital Zhejiang University, Southern Medical University, Nanfang Hospital, Fudan University, Zhongshan Hospital, Shanghai Jiao Tong University, Ruijin Hospital, Xijing Hospital, Zhejiang Yongning Pharma (China), Beijing Chao-Yang Hospital, People's Liberation Army No. 150 Hospital, Peking University, Peking University Cancer Hospital, Peking University Third Hospital, General Hospital of Guangzhou Military Command